[T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
HER2-targeted therapy for HER2-positive breast cancer is one of the success stories in medical oncology. Trastuzumab, a humanized monoclonal antibody, was the first approved HER2-targeted agent. Subsequent developments include agents with different mechanisms, such as lapatinib, a tyrosine kinase inhibitor. We describe here the results of late-phase clinical trials of two newly-available anti-HER2 agents, T-DM1 and pertuzumab.